Pharm 1- Hematology Drugs

69 Questions

Settings
Please wait...
Pharm 1- Hematology Drugs

Review quiz based on pharmacology lecture on Hematology


Questions and Answers
  • 1. 
    Which of the following does not contribute to thrombosis?
    • A. 

      Blood flow abnormalities

    • B. 

      Contact surface abnormalities

    • C. 

      Complement abnormalities

    • D. 

      None of the above

  • 2. 
    Vrichow's Triad features 3 broad catergories of Factors that prevent thrombosis
    • A. 

      True

    • B. 

      False

  • 3. 
    The non-living fluid matrix of blood is called
    • A. 

      Formed elements

    • B. 

      Connective tissue

    • C. 

      Plasma

    • D. 

      None of the above

  • 4. 
    Thrombocytes are a part of plasma
    • A. 

      True

    • B. 

      False

  • 5. 
    Which of the following is not found dissolved in plasma
    • A. 

      Proteins

    • B. 

      Nutrients

    • C. 

      Platelets

    • D. 

      Waste products

    • E. 

      None of the above

  • 6. 
    Which plasma protein is converted to form the basic framework for a blood clot
    • A. 

      Globulin

    • B. 

      Fibrinogen

    • C. 

      Albumin

    • D. 

      Bilirubin

  • 7. 
    Pt. presents with liver disorder, which of the following is least likely to result from this
    • A. 

      Increased synthesis of vitamin K

    • B. 

      Decreased synthesis of Fibrinogen

    • C. 

      Clotting factor problems

    • D. 

      Decreased plasma protein levels

    • E. 

      None of the above

  • 8. 
    When megakaryocytes shed their cytoplasm into small membrane enclosed packets these packets leave the bone marrow and enter the blood to become
    • A. 

      Red blood cells

    • B. 

      Platelets

    • C. 

      Lymphocytes

    • D. 

      Mast cells

  • 9. 
    Platelets aid in which one of the major functions of blood?
    • A. 

      Regulation of pH & ion concentration of interstitial fluids

    • B. 

      Defense against toxins and pathogens

    • C. 

      Stabilization of body temperature

    • D. 

      Transportation of nutrients hormones, wastes and dissolved gasses

    • E. 

      Restriction of fluid losses at injury sites

  • 10. 
    • A. 

      True

    • B. 

      False

  • 11. 
    Which of the following would affect hemostatis
    • A. 

      Vit. k synthesis

    • B. 

      Clotting factors

    • C. 

      Liver disorder

    • D. 

      All of the above

  • 12. 
    Normal clotting occurs in __________ minutes
    • A. 

      2

    • B. 

      6

    • C. 

      12

    • D. 

      15

  • 13. 
    Extrinisc pathway  is activated by
    • A. 

      Abnormal vessel wall in the absence of injury

    • B. 

      tissue injury

    • C. 

      All of the above

  • 14. 
    An abnormal vessel wall in the absense of injury may activate clotting through the _________ pathway
    • A. 

      Intrinsic

    • B. 

      Extrinsic

    • C. 

      Contact activation

    • D. 

      A & C

    • E. 

      None of the above

  • 15. 
    Hemostasis is the process that halts bleeding, which of its following phases are the last to occur
    • A. 

      Coagulation

    • B. 

      Vascular spasms

    • C. 

      platelet plug formation

  • 16. 
    During the Vascular phase of Hemostasis serotonin causes
    • A. 

      Platelets to pile up to form a platelet plug

    • B. 

      Blood vessel to spasm

    • C. 

      Complement activation

    • D. 

      Drowsiness

  • 17. 
    The exposure of collagen fibers in a broken blood vessel initiate which stage of hemostasis
    • A. 

      Vascular spasm

    • B. 

      Platelet plug formation

    • C. 

      Coagulation

    • D. 

      None of the above

  • 18. 
    During the coagulation phase of hemostasis platelets release thromboplastin which combines with clotting factors and triggers the clotting cascade
    • A. 

      True

    • B. 

      False

  • 19. 
    Which is the correct chronological order of the clotting cascade
    • A. 

      Prothrombin activator -> thrombin -> prothrombin-> fibrinogen-> fibrin-> meshwork

    • B. 

      Meshwork-> thrombin->prothrombin activator-> prothrombin->fibrin-> fibrinogen

    • C. 

      Prothrombin activator-> Prothrombin-> Thrombin-> Fibrinogen-> Fibrin-> Meshwork

    • D. 

      Fibrin-> fibrinogen-> Prothrombin->thrombin-> Meshwork

  • 20. 
    Coagulation lab studies include all of the following except
    • A. 

      Platelet count

    • B. 

      INR

    • C. 

      PT

    • D. 

      PTT

    • E. 

      PPD

  • 21. 
    Lab tests reveal patient does not have enough platelets and tiny blood clots are "eating" platelets. This patient is suffering from
    • A. 

      Sickle Cell Anemia

    • B. 

      Thrombotic Thrombocytopenic Purpura

    • C. 

      Idiopathic thrombocytopenia

    • D. 

      None of the above

  • 22. 
    Lab studies reveal the patient's platelets are being coated with IgG and are not being recognized as self. As a result, macrohpages are destroying the platelets. This is dx as ________
    • A. 

      Thrombotic thrombocytopenic purpura

    • B. 

      Idiopathic thrombocytopenia

    • C. 

      Disseminated intravascular coagulation

    • D. 

      None of the above

  • 23. 
    Lab tests reveal that your patient is experiencing pathological activation of the clotting cascade and there are multiple little blood clots all through out the vasculature this consumption of clotting factors and platelets will lead to
    • A. 

      Disseminated intravascular coagulation

    • B. 

      TTP

    • C. 

      Bleeding

    • D. 

      A & C

    • E. 

      All of the above

  • 24. 
    Which of the following is correct
    • A. 

      Von Willebrand's Disease - Factor IX deficient

    • B. 

      Hemophilia B (Christmas Disease) - Factor VII deficient

    • C. 

      Hemophilia A - Factor IX deficient

    • D. 

      None of the above

  • 25. 
    Hemophilia and Von Willebrand's disease are hereditary
    • A. 

      True

    • B. 

      False

  • 26. 
    Inhibits specific clotting factors and interfere with the clotting cascade and thrombin formation
    • A. 

      Anticoagulants

    • B. 

      Antiplatelet agents

    • C. 

      Thrombolytics

    • D. 

      None of the above

  • 27. 
    Anti-platelet agents interfere with the clotting cascade at the point of
    • A. 

      Thrombin formation

    • B. 

      Formation of the platelet plug

    • C. 

      Steps leading to fibrin formation

    • D. 

      None of the above

  • 28. 
    Which is not a drug for coagulation disorders
    • A. 

      Anticoagulants

    • B. 

      Antiplatelets

    • C. 

      Thrombolytics

    • D. 

      None of the above

  • 29. 
    Anticoagulants directly or indirectly inhibit thrombin formation
    • A. 

      True

    • B. 

      False

  • 30. 
    Anticoagulants inhibit specific clotting factors and interfere with steps leading to fibrin formation
    • A. 

      True

    • B. 

      False

  • 31. 
    Which of the following is true about anticoagulants
    • A. 

      They only directly inhibit thrombin formation

    • B. 

      Inhibit all clotting factors that lead to fibrin formation

    • C. 

      Prevent formation of new clots or enlargement of existing ones

    • D. 

      Dissolve existing clots

    • E. 

      All of the above

  • 32. 
    Promotes formation of new clots
    • A. 

      Thrombolytics

    • B. 

      Anticoagulants

    • C. 

      Hemostatics

    • D. 

      Antiplatelet

  • 33. 
    Thrombolytics break down an existing thrombus by stimulating the _________system
    • A. 

      Fibrin

    • B. 

      Plasmin

    • C. 

      Thrombin

    • D. 

      Complement

    • E. 

      None of the above

  • 34. 
    Efficacy of the extrinsic pathway is evaluated by
    • A. 

      PT

    • B. 

      PTT

    • C. 

      INR

    • D. 

      A & C

    • E. 

      All of the above

  • 35. 
    Evaluates the efficacy of both intrinsic and common pathways
    • A. 

      PT

    • B. 

      PTT

    • C. 

      INR

    • D. 

      A & C

    • E. 

      All of the above

  • 36. 
    Measures time needed to form clot after addition of TF (factor III)
    • A. 

      PT

    • B. 

      PTT

    • C. 

      INR

    • D. 

      A & C

    • E. 

      All of the above

  • 37. 
    Used to standardize PT results due to variations in manufacturer's TF
    • A. 

      PT

    • B. 

      PTT

    • C. 

      INR

    • D. 

      A & C

    • E. 

      All of the above

  • 38. 
    PTT is essentially the same as PT but without TF added
    • A. 

      True

    • B. 

      False

  • 39. 
    Which of the following is not an Anticoagulant
    • A. 

      Warfarin

    • B. 

      Dalteparin (Sub Q)

    • C. 

      Heparin

    • D. 

      Ticlopidine (Ticlid) (PO)

    • E. 

      Antithrombin (IV)

  • 40. 
    Which of the following is not  a Sub Q anticoagulant
    • A. 

      Dalteparin

    • B. 

      Fondapirinux

    • C. 

      Heparin Sodium

    • D. 

      Warfarin

    • E. 

      Enoxaparin (Lovenox)

  • 41. 
    Used in conjunction with ASA to prevent blood clots during transluminal coronary angioplasty
    • A. 

      Argatroban

    • B. 

      Antithrombin ( Thrombate III)

    • C. 

      Bivalrudin ( angiomax)

    • D. 

      Fondapirinux (Arixta)

  • 42. 
    Used to prevent thrombosis in heparin induced thrombocytopenia
    • A. 

      Bivalrudin (Angiomax)

    • B. 

      Argatroban

    • C. 

      Antithrombin

    • D. 

      Dalterparin (Fragmin)

  • 43. 
    Used to treat HIT and other thromboembolic disorders
    • A. 

      Lepirudin ( Refludan)

    • B. 

      Fondapirinux (Arixtra)

    • C. 

      Bivalrudin (angiomax)

    • D. 

      Antrithrombin ( thrombate III)

  • 44. 
    Indicated for DVT prophylaxis in surgical patients
    • A. 

      Dalteparin (Fragmin)

    • B. 

      Argatroban

    • C. 

      Antithrombin (Thrombate III)

    • D. 

      Fondapirinux (Arixtra)

  • 45. 
    Low molecular weight heparin
    • A. 

      Warfarin ( Coumadin)

    • B. 

      Heparin Sodium

    • C. 

      Dalteparin (Fragmin)

    • D. 

      Alteplase (Activase)

    • E. 

      None of the above

  • 46. 
    Interferes with hepatic synthesis of vitamin K-dependent clotting factors
    • A. 

      Heparin Sodium

    • B. 

      Warfarin (Coumadin)

    • C. 

      Urokinase ( Abbokinase

    • D. 

      Alteplase (Activase)

  • 47. 
    Warfarin (Coumadin)  is contraindicated during pregnancy, and the PT and INR values of patients taking warfarin should be monitored
    • A. 

      True

    • B. 

      False

  • 48. 
    Has multiple drug/drug interactions and may cause tissue necrosis
    • A. 

      Heparin Sodium

    • B. 

      Enoxaparin (Lovenox)

    • C. 

      Warfarin (Coumadin)

    • D. 

      Alteplase (Activase)

    • E. 

      None of the above

  • 49. 
    Inhibits conversion of fibrinogen to fibrin
    • A. 

      Heparin

    • B. 

      Alteplase (Activase)

    • C. 

      Tirofiban (aggrastat)

    • D. 

      None of the above

  • 50. 
    During pregnancy LMW Heparin is the better choice of UF heparin
    • A. 

      True

    • B. 

      False

  • 51. 
    Which is a thrombolytic Enzyme Fibrinolytic
    • A. 

      Alteplase (Activase)

    • B. 

      Urokinase (Abbokinase)

    • C. 

      Reteplase (Retavase)

    • D. 

      None of the above

  • 52. 
    TPA converts plasminogen to plasmin->digests Fibrin -> dissolves blood clot
    • A. 

      Alteplase(Activase)

    • B. 

      Anticoagulants

    • C. 

      Eptifibatide (integrilin)

    • D. 

      Tirofiban ( Aggrastat)

  • 53. 
    Which of the following is an IV Antiplatelet agent
    • A. 

      Aspirin

    • B. 

      Eptifibatide (Integrilin)

    • C. 

      Clopidrogel (Plavix)

    • D. 

      Ticlopidine (Ticlid)

  • 54. 
    Which Anti platelet Agent is PO
    • A. 

      Clopidrogel (Plavix)

    • B. 

      Eptifibatide (Integrilin)

    • C. 

      Abciximab (Reopro)

    • D. 

      Tirfiban ( Aggrastat)

  • 55. 
    IV antiplatelets are used for the following except
    • A. 

      Acute coronary syndrome (ACS)

    • B. 

      Percutaneous Coronary Intervention (PCI)

    • C. 

      Promote Thrombi

    • D. 

      Prolong bleeding time

  • 56. 
    Inhibits platelet aggregation by inhibiting platelet synthesis of thromboxane A
    • A. 

      Alteplase (Activase)

    • B. 

      Aspirin

    • C. 

      Urokinase (Abbokinase)

    • D. 

      Dalteparin (fragmin)

  • 57. 
    Parasitic protozoa such as Plasmodium Falciparum, live in or on humans and can cause Malaria
    • A. 

      True

    • B. 

      False

  • 58. 
    Most widespread plasmodium world wide
    • A. 

      Vivax

    • B. 

      Malaria

    • C. 

      Falciparum

    • D. 

      Ovale

  • 59. 
    The sexual cycle of Plasmodium occurs while it is in the human host. This is the time when it is most susceptible to drugs.
    • A. 

      True

    • B. 

      False

  • 60. 
    Which of the following malaria drugs is effective during the exoerythrocytic phase of the plasmodium life cycle
    • A. 

      Chloroquine (Aralen)

    • B. 

      Quinine ( Qualaquin)

    • C. 

      Mefloquin (lariam)

    • D. 

      Primaquine

  • 61. 
    4-aminoquinoline derivatives do all of the following except
    • A. 

      Inhibits protein synthesis

    • B. 

      Alter parasites pH

    • C. 

      Interfere with parasite's ability to use hemoglobin

    • D. 

      None of the above

  • 62. 
    Pyrimethamine & trimethoprim block parasitic function by increasing tetrahydrofolate synthesis
    • A. 

      True

    • B. 

      False

  • 63. 
    For prophylaxis antimalaria drugs should be started _____weeks before potential exposure and continue for _________weeks after leaving the area
    • A. 

      2, 8

    • B. 

      8, 8

    • C. 

      2, 2

    • D. 

      8, 2

  • 64. 
    Antimalaria medications have primarily _____________side effect
    • A. 

      Cardiac

    • B. 

      GI

    • C. 

      Respiratory

    • D. 

      None of the above

  • 65. 
    Which of the following does not need to be monitored for a patient on antimalrial drugs
    • A. 

      Tinnitus

    • B. 

      PPT

    • C. 

      Decreased hearing

    • D. 

      Visual difficulties

    • E. 

      All of the above

  • 66. 
    The following picture representsthe picture represents
    • A. 

      Intracellular parasite

    • B. 

      Fibrin clot

    • C. 

      Hemorrhage

    • D. 

      All of the above

  • 67. 
    The following representsThe picture represents
    • A. 

      Plasmodium falciparum

    • B. 

      Plasmodium vivax

    • C. 

      Plasmodium malaria

    • D. 

      None of the above

  • 68. 
    The picture representsThe picture represents
    • A. 

      Plasmodium vivax

    • B. 

      Plasmodium falciparum

    • C. 

      Plasmodium malaria

    • D. 

      None of the above

  • 69. 
    This representsThis represents
    • A. 

      Plasmodium Vivax

    • B. 

      Virus Cell

    • C. 

      Plasmodum Falciparum

    • D. 

      E. Coli